AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01964027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second line chemoregime for advanced gastric cancer
Description: Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
Study NCT02055729 — intervention group
Intervention type: BIOLOGICAL
Intervention: 3mm tissue punch biopsy
Description: Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
Study NCT02055729 — intervention group
Intervention type: BIOLOGICAL
Intervention: Superficial bedsore sample
Description: Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
Study NCT02055729 — intervention group
Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: Stool samples will be collected on days 0 and 28.
Study NCT02055729 — intervention group
Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine samples will be collected on days 0 and 28.
Study NCT03613168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab plus gemcitabine/cisplatin
Study NCT02145754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MKP media
Description: one half of skin specimen was put in MKP media
Study NCT02145754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSK-H media
Description: one half of skin specimen was put in BSK-H media
Study NCT03185091 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rapid ventricular pacing
Study NCT03185091 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Study NCT01200563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
Study NCT01200563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure
Description: Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
Study NCT01200563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy and Negative Pressure Wound Therapy
Description: MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
Study NCT04287205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: 79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
Study NCT04873804 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Study NCT01575236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Laryngeal Mask
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
Study NCT01575236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
Study NCT02634775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in treatment strategy
Description: Start on dialysis, transplantation, change of PD prescription, change of HD prescription
Study NCT02974140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract Refractive Suite (CRS)
Description: Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
Study NCT02974140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Refractive Suite (CRS)
Description: Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
Study NCT02974140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard manual technique
Description: Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
Study NCT02974140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard manual technique
Description: Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
Study NCT00814580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Description: First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
Study NCT00814580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
Study NCT01905943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
Study NCT01905943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
Study NCT01905943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
Study NCT01905943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
Study NCT01905943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
Study NCT01020409 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac surgery with CPB use
Description: cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
Study NCT03573206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)
Description: The device will be used to close all femoral venous access sites at the end of the case.
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Study NCT00717132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Behavior Modification
Description: Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02469987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYL-1402O
Description: Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
Study NCT02469987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US marketed Avastin(R)
Description: Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
Study NCT02469987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU marketed Avastin(R)
Description: Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
Study NCT03370419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
Study NCT03370419 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT03451513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pride Body Project
Description: PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity.
Study NCT03451513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Media Advocacy
Description: We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
Study NCT04119804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cellular neural networks-genetic algorithm
Description: Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
Study NCT04599491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'
Description: Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
Study NCT04599491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'
Description: Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
Study NCT04242628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook course
Description: The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
Study NCT04242628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Course
Description: The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
Study NCT02651259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: 900 mg of RPT
Study NCT01422941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAVU Attune Device
Description: The CAVU Attune device is used with LAGB.
Study NCT02651259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: 900 mg of INH
Study NCT00107432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00107432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02651259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: 25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Study NCT00255983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem medoxomil
Description: 600 mg BID for 5 days
Study NCT00255983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets BID for 5 days
Study NCT00547989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard anaesthesia (bupivacaine)
Description: Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
Study NCT01004653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 influenza A Vaccine (Split virion), Inactivated
Description: 100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
Study NCT03915028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water
Study NCT00524732 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular
Study NCT00547989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: additional pvb (ropivacaine) and elastomeric disposable infusion pump
Description: Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
Study NCT05529667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054828, Paclitaxel
Description: phase 1>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent.
Study NCT02013674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hMSCs
Description: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
Study NCT02410980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.1%
Description: Assessment of the skin change
Study NCT03620968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: 15 minutes day of brain training by an APP
Study NCT00351533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Description: Liquid fish oil 7.5cc enterally every 6 hours
Study NCT00351533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Description: Liquid fish oil 7.5cc enterally every 6 hours
Study NCT00430820 — intervention group
Intervention type: PROCEDURE
Intervention: per intervention
Description: per intervention
Study NCT00547989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: additional pvb (ropivacaine)
Description: Patients in group 1 will receive PVB with ropivacaine
Study NCT00189436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Budesonide
Description: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
Study NCT00189436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (albuterol with or without oral steroid)
Description: Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
Study NCT01666015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE (EX)
Description: This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games).
Study NCT00662831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin/ Dalteparin Sodium
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
Study NCT00662831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Fragmin/ Dalteparin Sodium
Description: Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
Study NCT01666015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: This group will be under standard care without any EX intervention.
Study NCT04396327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: diphenhydramine, zolpidem and lorazepam
Study NCT04396327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: diphenhydramine and lorazepam
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Study NCT01479244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuVax™ vaccine
Description: E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
Study NCT01479244 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leukine® (sargramostim, GM-CSF) and water for injection
Description: Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
Study NCT02580032 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given.
Study NCT03789656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, capsules, once daily by mouth
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Study NCT00705380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents
Description: CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.